Novartis reports a Phase III failure for del-desiran and anticipates data for pelacarsen in collaboration with Ionis Pharmaceuticals.
Novartis is experiencing clinical setbacks, including a Phase III failure for the drug del‑desiran.
The company also expects data for pelacarsen, a program conducted alongside Ionis Pharmaceuticals.
Further verified details were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
